255 related articles for article (PubMed ID: 34024774)
21. FSHD myotubes with different phenotypes exhibit distinct proteomes.
Tassin A; Leroy B; Laoudj-Chenivesse D; Wauters A; Vanderplanck C; Le Bihan MC; Coppée F; Wattiez R; Belayew A
PLoS One; 2012; 7(12):e51865. PubMed ID: 23272181
[TBL] [Abstract][Full Text] [Related]
22. Dynamic transcriptomic analysis reveals suppression of PGC1α/ERRα drives perturbed myogenesis in facioscapulohumeral muscular dystrophy.
Banerji CRS; Panamarova M; Pruller J; Figeac N; Hebaishi H; Fidanis E; Saxena A; Contet J; Sacconi S; Severini S; Zammit PS
Hum Mol Genet; 2019 Apr; 28(8):1244-1259. PubMed ID: 30462217
[TBL] [Abstract][Full Text] [Related]
23. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
24. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
25. Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy.
Chen L; Kong X; Johnston KG; Mortazavi A; Holmes TC; Tan Z; Yokomori K; Xu X
Genome Res; 2024 Jun; 34(5):665-679. PubMed ID: 38777608
[TBL] [Abstract][Full Text] [Related]
26. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
Jagannathan S
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
[TBL] [Abstract][Full Text] [Related]
27. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
28. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
29. Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4.
Homma S; Beermann ML; Yu B; Boyce FM; Miller JB
Skelet Muscle; 2016 Dec; 6(1):42. PubMed ID: 27906075
[TBL] [Abstract][Full Text] [Related]
30. Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei.
Jiang S; Williams K; Kong X; Zeng W; Nguyen NV; Ma X; Tawil R; Yokomori K; Mortazavi A
PLoS Genet; 2020 May; 16(5):e1008754. PubMed ID: 32365093
[TBL] [Abstract][Full Text] [Related]
31. RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy.
Mariot V; Joubert R; Le Gall L; Sidlauskaite E; Hourde C; Duddy W; Voit T; Bencze M; Dumonceaux J
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2079-2090. PubMed ID: 34687171
[TBL] [Abstract][Full Text] [Related]
32. Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.
Banerji CRS; Henderson D; Tawil RN; Zammit PS
Hum Mol Genet; 2020 Sep; 29(16):2746-2760. PubMed ID: 32744322
[TBL] [Abstract][Full Text] [Related]
33. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
[TBL] [Abstract][Full Text] [Related]
34. Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy.
Karpukhina A; Galkin I; Ma Y; Dib C; Zinovkin R; Pletjushkina O; Chernyak B; Popova E; Vassetzky Y
Redox Biol; 2021 Jul; 43():102008. PubMed ID: 34030118
[TBL] [Abstract][Full Text] [Related]
35. Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts.
Pandey SN; Khawaja H; Chen YW
Molecules; 2015 May; 20(5):8304-15. PubMed ID: 26007167
[TBL] [Abstract][Full Text] [Related]
36. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.
Moyle LA; Blanc E; Jaka O; Prueller J; Banerji CR; Tedesco FS; Harridge SD; Knight RD; Zammit PS
Elife; 2016 Nov; 5():. PubMed ID: 27841748
[TBL] [Abstract][Full Text] [Related]
37. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).
Jones TI; Parilla M; Jones PL
PLoS One; 2016; 11(3):e0150938. PubMed ID: 26942723
[TBL] [Abstract][Full Text] [Related]
38. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
39. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
40. Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target.
Heher P; Ganassi M; Weidinger A; Engquist EN; Pruller J; Nguyen TH; Tassin A; Declèves AE; Mamchaoui K; Banerji CRS; Grillari J; Kozlov AV; Zammit PS
Redox Biol; 2022 May; 51():102251. PubMed ID: 35248827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
